Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:
Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/esmo-breast-sat
In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see
Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)
Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors
Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)